Sciences Po Paris

Arthur Stril

Sciences Po Paris
Lecturer (Healthcare)

Arthur Stril is a Lecturer in Healthcare at Sciences Po in Paris. He has previously served as Head of Unit - Hospital Financing at the French Ministry of Social Affairs and Health (Ministère des solidarités et de la santé), and as Case Handler - Pharma Merger Control at the European Commission.

Auteurs associés

Sciences Po Paris
Sciences Po Paris
Ecole de droit (Sciences Po Paris)
Sciences Po Paris
Ecole de droit (Sciences Po Paris)


1497 Bulletin

Arthur Stril, Ivan Gasperec, Marion Bailly The EU Commission clears acquisition of a fourth largest global manufacturer of generic medicines by the largest global competitor, subject to complex remedies and monitoring, including addressing concerns about vertical relationships between parties for the first time in a generics merger (Teva / Allergan Generics)


Teva/Allergan Generics : An unprecedented generics merger* In a nutshell While the Commission has had significant experience dealing with mergers in the generic medicines industry, the sheer scale of Teva/Allergan Generics, combining two of the top four players globally, posed a number of (...)

Agata Mazurkiewicz-Gorgol, Arthur Stril The EU Commission clears acquisition of a pharmaceutical company, with effects in the market for biosimilars, subject to remedies that ensure innovation competition (Pfizer / Hospira)


Pfizer / Hospira : Through the lookingglass : assessing competition by biosimilars* In a nutshell In Pfizer/Hospira, the Commission assessed biosimilar drugs in detail for the first time. Biosimilars aim to have the same therapeutic mechanism as, and be clinically equivalent to, original (...)

Arthur Stril, Daniele Calisti, Marion Bailly The EU Commission conditionally approves the acquisition of a life science company affecting the market for laboratory chemicals (Merck / Sigma-Aldrich)


Merck/Sigma-Aldrich : the 200,000 products case* In a nutshell : In the life science case Merck/Sigma-Aldrich, the Commission focused for the first time on "laboratory chemicals", a term that covers hundreds of thousands of specialty chemicals. The Commission identified concerns regarding the (...)

Arthur Stril, Irene Mirabile, Lluís Saurí The EU Commission conditionally approves deals in the pharmaceutical sector extending its analysis of pipeline pharmaceutical products (Novartis / GSK)


"Protecting the drugs of tomorrow : competition and innovation in healthcare"* In a nutshell : In Novartis/GSK Oncology, the Commission extended its analysis of pipeline pharmaceutical products beyond those that are in advanced stages of development (phase III), to fully assess the (...)

Arthur Stril, Geneviève Lallemand-Kirche, Laura Seritti, Luca Di Martile The EU Commission approves the acquisition of several chemical businesses, subject to conditions (Huntsman / Rockwood)


"The "White Powder" Case : Balancing the Evidence"* The Huntsman- Rockwood TiO2 merger provides lessons for future chemical cases on the following topics : 1) The use of market features and price correlation to define relevant market. 2) Competition by Chinese products in the (...)

Envoyer un message